Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Some Drug Prices Could Drop 40% Under Canada’s Cost Lowering Proposals

Executive Summary

The prices of patented medicines overall are expected to go down in Canada under new proposed regulatory amendments.

You may also be interested in...



Canada Overhauls Drug Pricing, But Devil Will Be In The Detail

Long awaited changes to Canada’s Patented Medicines Regulations have been announced, but companies will have to wait for new guidelines from the pricing watchdog to better understand how they will be implemented.

Generics Firms Swap Tendering For Price Cuts In Canada

Generic drug manufacturers in Canada have agreed to price cuts of up to 40% to stave off tendering.

Canada Plans To Force Firms To Disclose Confidential Pricing Deals

Companies operating in Canada could face pharmacoeconomic evaluations to decide if drugs are over-priced as well as a requirement to disclose information that could impair the confidentiality of pricing agreements.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS122109

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel